HIGHLIGHTS
- who: Abdul Rashid Issahaku from the School University of have published the Article: Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy, in the Journal: Scientific Reports Scientific Reports
- what: Oncogenic KRAS has eluded drug developers for decades until covalent inhibition was strategically employed to target the mutated cysteine within the switch II binding pocket.
- how: To highlight the percentage of time occupied by these interactions in the 450 ns simulation period the hydrogen_bond occupancy was calculated and presented in Table 1.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.